Related Experiment Video
Updated: Mar 29, 2026

Detection of Low Copy Number Integrated Viral DNA Formed by In Vitro Hepatitis B Infection
Published on: November 7, 2018
[Update Chronic Viral Hepatitis B and C]
Benedetta Terziroli Beretta-Piccoli1, Melanie Schranz1,2, Andrea De Gottardi1,2
11 Epatocentro Ticino, Lugano.
Insights
Chronic hepatitis B (HBV) infection can persist lifelong, but inactive carrier status is a therapeutic goal. Hepatitis C treatment is recommended for advanced fibrosis, with new direct antivirals offering high efficacy and safety.
Area of Science:
- Hepatology
- Virology
- Immunology
Context:
- Chronic hepatitis B (HBV) infection presents a complex natural history influenced by infection age, comorbidities, and coinfections.
- HBV persists lifelong in hepatocytes, making complete viral elimination unachievable.
- Chronic hepatitis C (HCV) can progress to liver cirrhosis in 30% of cases, necessitating treatment for significant fibrosis.
Purpose:
- To outline the management of chronic hepatitis B and C.
- To highlight therapeutic goals and available treatments for HBV.
- To define treatment indications for HCV based on fibrosis staging.
Summary:
- HBV infection management aims for inactive carrier status using pegylated interferon or direct antivirals, alongside prophylactic screening and vaccination.
- HCV treatment is advised for Metavir fibrosis stage 2 or higher, with newer direct-acting antivirals (DAAs) providing short, effective, and safe regimens.
Impact:
- Effective management strategies can prevent disease progression and improve patient outcomes.
- Prophylactic measures like vaccination are crucial for controlling HBV transmission.
- Advances in DAAs have revolutionized HCV treatment, offering high cure rates with minimal side effects.
Abstract:
Chronic hepatitis B has a complex natural history. The age at infection, comorbidities, coinfections, and other, yet to be identified factors, determine the probability of developing a chronic infection. The HBV virus can never be completely eliminated and remains in the hepatocytes for life. However, to reach an inactive carrier status is a realistic goal of the therapy. For HBV treatment, pegylated interferon and direct antivirals are available. To screen persons at risk and to vaccinate all of the population are important prophylactic measures. Chronic hepatitis C infection leads, in 30% of cases, to liver cirrhosis. Treatment is recommended from fibrosis stage Metavir 2. New DAA allows short treatment, with a high response rate and very few adverse effects.
Related Concept Videos
Hepatitis
Cytomegalovirus Disease
Viruses with RNA Genomes
Mechanisms of Retrovirus-induced Cancers
Chronic Pancreatitis I: Introduction
Pancreatitis is the inflammation of the pancreas, which occurs when the immune system becomes active and causes swelling, pain, and disruptions in organ function. Pancreatitis can manifest as either an acute or chronic condition.
Acute pancreatitis arises suddenly and lasts for a brief duration, while chronic pancreatitis is a long-term affliction...
Inhibitors of Viral Protein Synthesis

